

## Zydelig<sup>®</sup> (idelalisib) (Oral)

Document Number: IC-0206

Last Review Date: 07/05/2023

Date of Origin: 08/26/2014

Dates Reviewed: 08/2014, 07/2015, 07/2016, 08/2017, 07/2018, 07/2019, 07/2020, 07/2021, 04/2022,  
07/2023

### I. Length of Authorization

Coverage will be provided for 6 months and may be renewed.

### II. Dosing Limits

#### A. Quantity Limit (max daily dose) [NDC Unit]:

- Zydelig 100 mg tablets: 2 tablets per day
- Zydelig 150 mg tablets: 2 tablets per day

#### B. Max Units (per dose and over time) [HCPCS Unit]:

- 300 mg per day

### III. Initial Approval Criteria <sup>1</sup>

Coverage is provided for the following conditions:

- Patient is at least 18 years of age; **AND**

#### Universal Criteria <sup>1</sup>

- Patient will avoid concomitant therapy with all of the following:
  - Coadministration with strong CYP3A inducers (e.g., rifampin, carbamazepine, St. John's Wort, etc.); **AND**
  - Coadministration with strong CYP3A inhibitors (e.g., itraconazole, ketoconazole, clarithromycin, etc.), or if therapy is unavoidable, the patient will be monitored closely for adverse reaction and/or dose modifications; **AND**
- Patient has not received previous therapy with a small-molecule inhibitor (phosphatidylinositol-3 kinase inhibitor [PI3-K]) therapy (e.g., alpelisib, copanlisib, duvelisib, umbralisib, leniolisib, etc.); **AND**
- Patient does not have an active infection, including clinically important localized infections; **AND**

- Patient will receive prophylactic therapy for *Pneumocystis jirovecii pneumonia* (PJP) while on treatment with idelalisib; **AND**
- Baseline ALT and AST will be obtained prior to initiating treatment and monitored periodically while on treatment; **AND**

#### Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) † ‡ Φ <sup>1-5</sup>

- Used as a single agent or in combination with rituximab; **AND**
  - Used for disease without the del(17p)/TP53 mutation; **AND**
    - Used as subsequent therapy for relapsed or refractory disease; **AND**
    - Patient has received prior therapy with Bruton Tyrosine Kinase (BTK) inhibitor (e.g., ibrutinib, acalabrutinib, zanubrutinib) and venetoclax-based regimens; **OR**
  - Used for disease with the del(17p)/TP53 mutation; **AND**
    - Used as second-line or third-line therapy

† FDA Approved Indication(s); ‡ Compendia Recommended Indication(s); Φ Orphan Drug

#### IV. Renewal Criteria <sup>1</sup>

Coverage can be renewed based upon the following criteria:

- Patient continues to meet the universal and other indication-specific relevant criteria such as concomitant therapy requirements (not including prerequisite therapy), performance status, etc. identified in Section III; **AND**
- Disease response with treatment as defined by stabilization of disease or decrease in size of tumor or tumor spread; **AND**
- Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include: serious infections, neutropenia, severe diarrhea or colitis, hepatotoxicity, pneumonitis, intestinal perforation, severe cutaneous reactions [Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)], hypersensitivity reactions/anaphylaxis, etc.

#### V. Dosage/Administration <sup>1</sup>

Indication	Dose
CLL/SLL	Administer 150 mg by mouth twice daily until disease progression or unacceptable toxicity

#### VI. Billing Code/Availability Information

HCPCS Code:

- J8999 – Prescription drug, oral, chemotherapeutic, NOS

NDC(s):

- Zydelig 100 mg tablets: 61958-1701-xx

- Zydelig 150 mg tablets: 61958-1702-xx

## VII. References

1. Zydelig [package insert]. Foster City, CA; Gilead; February 2022. Accessed June 2023.
2. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for idelalisib. National Comprehensive Cancer Network, 2023. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed June 2023.
3. Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. *N Engl J Med.* 2014 Mar 13;370(11):997-1007. doi: 10.1056/NEJMoa1315226. Epub 2014 Jan 22.
4. Gopal AK, Kahl BS, de Vos S, et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. *N Engl J Med.* 2014 Mar 13;370(11):1008-18. doi: 10.1056/NEJMoa1314583. Epub 2014 Jan 22.
5. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Version 3.2023. National Comprehensive Cancer Network, 2023. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Guidelines, go online to NCCN.org. Accessed June 2023

## Appendix 1 – Covered Diagnosis Codes

ICD-10	ICD-10 Description
C83.00	Small cell B-cell lymphoma, unspecified site
C83.01	Small cell B-cell lymphoma, lymph nodes of head, face and neck
C83.02	Small cell B-cell lymphoma, intrathoracic lymph nodes
C83.03	Small cell B-cell lymphoma, intra-abdominal lymph nodes
C83.04	Small cell B-cell lymphoma, lymph nodes of axilla and upper limb
C83.05	Small cell B-cell lymphoma, lymph nodes of inguinal region and lower limb
C83.06	Small cell B-cell lymphoma, intrapelvic lymph nodes
C83.07	Small cell B-cell lymphoma, spleen
C83.08	Small cell B-cell lymphoma, lymph nodes of multiple sites
C83.09	Small cell B-cell lymphoma, extranodal and solid organ sites
C91.10	Chronic lymphocytic leukemia of B-cell type not having achieved remission
C91.12	Chronic lymphocytic leukemia of B-cell type in relapse

## Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) may exist and compliance with these policies is required where applicable. They can be found at: <https://www.cms.gov/medicare-coverage-database/search.aspx>. Additional indications may be covered at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD/LCA): N/A

Medicare Part B Administrative Contractor (MAC) Jurisdictions		
Jurisdiction	Applicable State/US Territory	Contractor
E (1)	CA, HI, NV, AS, GU, CNMI	Noridian Healthcare Solutions, LLC
F (2 & 3)	AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ	Noridian Healthcare Solutions, LLC
5	KS, NE, IA, MO	Wisconsin Physicians Service Insurance Corp (WPS)
6	MN, WI, IL	National Government Services, Inc. (NGS)
H (4 & 7)	LA, AR, MS, TX, OK, CO, NM	Novitas Solutions, Inc.
8	MI, IN	Wisconsin Physicians Service Insurance Corp (WPS)
N (9)	FL, PR, VI	First Coast Service Options, Inc.
J (10)	TN, GA, AL	Palmetto GBA, LLC
M (11)	NC, SC, WV, VA (excluding below)	Palmetto GBA, LLC
L (12)	DE, MD, PA, NJ, DC (includes Arlington & Fairfax counties and the city of Alexandria in VA)	Novitas Solutions, Inc.
K (13 & 14)	NY, CT, MA, RI, VT, ME, NH	National Government Services, Inc. (NGS)
15	KY, OH	CGS Administrators, LLC